Ram Sasisekharan
Directeur/Membre du Conseil chez Harvard Mit Health Sciences & Technology
Profil
Ram Sasisekharan is the founder of Visterra, Inc. (founded in 2007), Momenta Pharmaceuticals, Inc. (founded in 2001), and Cerulean Pharma, Inc. (founded in 2006).
He held the title of Director at Momenta Pharmaceuticals, Inc. in 2010 and Independent Director at Cerulean Pharma, Inc. in 2014-2015.
Dr. Sasisekharan is also the founder of Tychan Pte Ltd.
Dr. Sasisekharan's current job(s) include being the Director & Professor at Harvard Mit Health Sciences & Technology, Professor-Biological Engineering at Massachusetts Institute of Technology since 2013, and Professor at David H.
Koch Institute for Integrative Cancer Research.
Dr. Sasisekharan's education history includes a graduate degree from Harvard University, an undergraduate degree from the University of Bangalore, and a doctorate degree from Harvard Medical School.
Postes actifs de Ram Sasisekharan
| Sociétés | Poste | Début |
|---|---|---|
| Massachusetts Institute of Technology | Corporate Officer/Principal | 01/01/1996 |
| Harvard Mit Health Sciences & Technology | Directeur/Membre du Conseil | 10/01/2011 |
David H. Koch Institute for Integrative Cancer Research
 David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Anciens postes connus de Ram Sasisekharan
| Sociétés | Poste | Fin |
|---|---|---|
Cerulean Pharma, Inc.
 Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Fondateur | 26/06/2015 |
| MOMENTA PHARMACEUTICALS, INC. | Fondateur | 10/09/2010 |
Tychan Pte Ltd.
 Tychan Pte Ltd. BiotechnologyHealth Technology Tychan Pte Ltd. is a clinical-stage biotechnology company based in Singapore that focuses on developing life-saving treatments for emerging infections through disruptive technologies. Tychan was founded by Professor Ram Sasisekharan of Massachusetts Institute of Technology (MIT)/Singapore MIT Alliance for Research and Technology (SMART) and Professor Ooi Eng Eong of Duke-National University of Singapore (Duke-NUS) Medical School, both of whom have expertise in biologics development and biology of acute viral infections. The private company is based in Singapore, Singapore, and Randall E. Woods has been the CEO of the company since 2021. The Singaporean company works closely with regulatory authorities to accelerate the translation from non-clinical studies to clinical trials for emerging pathogens. Temasek Holdings is the founding investor of Tychan. | Fondateur | - |
| VISTERRA INC | Fondateur | - |
Formation de Ram Sasisekharan
| Harvard University | Graduate Degree |
| University of Bangalore | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Visterra, Inc.
 Visterra, Inc. Pharmaceuticals: MajorHealth Technology Visterra, Inc. Is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antibody-based therapies for kidney diseases, and other chronic diseases. It focuses on its research technology platform, HIEROTOPE technology. The company was founded by Alan L. Crane, Kevin J. Bitterman and Ram Sasisekharan on December 20, 2007 and is headquartered in Waltham, MA. | Health Technology |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Health Technology |
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | Commercial Services |
Tychan Pte Ltd.
Tychan Pte Ltd. BiotechnologyHealth Technology Tychan Pte Ltd. is a clinical-stage biotechnology company based in Singapore that focuses on developing life-saving treatments for emerging infections through disruptive technologies. Tychan was founded by Professor Ram Sasisekharan of Massachusetts Institute of Technology (MIT)/Singapore MIT Alliance for Research and Technology (SMART) and Professor Ooi Eng Eong of Duke-National University of Singapore (Duke-NUS) Medical School, both of whom have expertise in biologics development and biology of acute viral infections. The private company is based in Singapore, Singapore, and Randall E. Woods has been the CEO of the company since 2021. The Singaporean company works closely with regulatory authorities to accelerate the translation from non-clinical studies to clinical trials for emerging pathogens. Temasek Holdings is the founding investor of Tychan. | Health Technology |
